13F Holdings
中文EN

OKYO OKYO Pharma Ltd IFRS Annual reports only

Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1849296

Financial factors as of 2025-03-31 (FY2025), by fiscal year; growth vs the previous fiscal year

Growth

TTM revenue YoY—
TTM net income YoY72.0%
TTM EPS YoY64.9%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE—
ROA-180.4%
ROIC (approx.)—
Asset turnover—

Leverage & solvency

Liabilities / assets250.9%
Debt / equity—
Current ratio0.40x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.38x
Accruals ratio-111.0%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Annual Quarterly (none) Export CSV 🔒
Line item FY2025*2025-03-31FY2024*2024-03-31FY2023*2023-03-31FY2022*2022-03-31FY2021*2021-03-31
Income statement
Revenue—————
R&D expense$2.25M$8.24M$6.34M$1.61M$348,347
Interest expense$878,174$1.05M$96,687—$1,123
Pretax income-$7.97M-$16.80M-$13.28M-$6.22M-$3.38M
Income tax$3.26M-$22,416$12,202$786,521$24,994
Net income-$4.71M-$16.83M-$13.27M-$5.43M-$3.35M
EPS (basic)-0.20-0.57-0.61-0.36-0.32
EPS (diluted)-0.20-0.57-0.61-0.36-0.32
Balance sheet
Cash & equivalents$1.56M$826,848$4.05M$2.70M$6.89M
Receivables——$592,195$812,956$43,370
Current assets$3.68M$1.54M$5.20M$4.30M$6.99M
PP&E, netmay include right-of-use assets (IFRS)$2,035$3,350$7,216$5,225$6,057
Total assets$3.68M$1.54M$5.20M$4.30M$7.09M
Current liabilities$9.23M$7.42M$7.26M$1.35M$1.71M
Short-term debt$2.70M————
Total liabilities$9.23M$7.42M$7.26M$1.35M$1.77M
Shareholders' equity-$5.55M-$5.88M-$2.05M$2.95M$5.32M
Cash flow statement
Operating cash flow-$1.81M-$9.49M-$7.70M-$5.47M-$1.60M
Capital expenditure$1,208—$5,916$1,669$6,943
Free cash flow-$1.81M—-$7.70M-$5.47M-$1.61M
Investing cash flow-$1,208—-$5,916-$1,669-$18,114
Financing cash flow$2.66M$6.21M$9.32M$2.15M$7.83M
Depreciation & amortization$2,563$3,866$3,797$2,423$1,512
Stock-based compensation$734,989$1.12M$1.29M$1.74M$550,138

Free plan shows the latest 5 periods; Pro shows all 6 🔒

· This company reports under IFRS: some line items differ from US GAAP — operating income is not required, interest expense may be broader "finance costs", and banks have no standard revenue line.

· This company files only annual reports with the SEC (20-F for foreign issuers), so there is no quarterly data; factors are by fiscal year and growth is vs the previous fiscal year.

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.